Taro gets FDA approval for biogeneric epilepsy drug
Industry sources: levetiracetam tablets had over $700 million in US sales in 2009.
Taro received FDA approval for four dosages of the tablets: 250 mg, 500 mg, 750 mg, and 1000 mg. According to industry sources, levetiracetam tablets had over $700 million in US sales in 2009.
Taro's share closed at $10.01 on Wall Street yesterday.
Published by Globes [online], Israel business news - www.globes-online.com - on February 2, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options